Preventive Vaccines Market Research Reveals Strong 9.8% CAGR Outlook Through 2030

The preventive vaccines sector has become a vital component of global healthcare, with its market witnessing substantial growth driven by ongoing efforts to combat infectious diseases. As immunization initiatives expand worldwide and new technologies emerge, this industry is set for remarkable progress in the coming years. Let's explore the current market value, growth drivers, key players, trends, and important segments shaping the preventive vaccines landscape.

Steady Growth in the Preventive Vaccines Market Size
The preventive vaccines market has seen strong expansion recently, increasing from $83 billion in 2025 to an anticipated $90.33 billion in 2026, representing a compound annual growth rate (CAGR) of 8.8%. This growth during the historical period can be linked to successful disease eradication efforts, government-backed vaccination campaigns, heightened public health awareness, global immunization programs, and increased financial backing from international health organizations.

Download a free sample of the preventive vaccines market report:
https://thebusinessresearchcompany.com/sample_request?id=28600657&type=smp&name=Preventive%20Vaccines%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Looking ahead, the market is poised for even faster growth, expected to reach $131.27 billion by 2030 at a CAGR of 9.8%. Factors propelling this forecast include advances in next-generation vaccine platforms, demographic changes such as population growth and urbanization, improved outbreak preparedness, expansion of adult vaccination programs, and strengthened collaborations between public and private sectors. Key trends during this period involve the broadening of national immunization schemes, greater emphasis on preventive healthcare, growing demand for vaccines targeting pediatric and elderly populations, the rise of combination and multivalent vaccines, and enhancements in cold chain logistics and storage systems.

Important Players Shaping the Preventive Vaccines Market
The preventive vaccines industry features a competitive lineup of leading companies, including Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, and Afrigen Biologics and Vaccines (Pty) Ltd.

View the full preventive vaccines market report:
https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

In a recent development in April 2024, European LifeCare Group, a UK-based vaccine manufacturer, acquired PreventVaccins B.V., a biotechnology firm from the Netherlands focused on preventive vaccines for infectious diseases. This acquisition strengthens European LifeCare Group's position in Europe and expands its vaccination offerings, particularly enhancing its presence in the Dutch market.

Technological Advances Fueling Growth in the Preventive Vaccines Industry
Vaccine developers are increasingly harnessing advanced technologies such as cutting-edge mRNA platforms to improve effectiveness, safety, and production speed while providing broader protection against evolving infectious disease variants. These mRNA platforms work by instructing cells to generate specific proteins that trigger a targeted immune response.

For example, in March 2025, Moderna Inc. announced FDA approval for mRNA-1283 (mNEXSPIKE), a next-generation COVID-19 vaccine authorized for adults 65 and older, as well as individuals aged 12 to 64 with certain risk factors defined by the CDC. This vaccine offers improved stability and easier storage compared to earlier versions, making it more accessible and practical for distribution-especially in underserved or remote locations.

Detailed Segmentation of the Preventive Vaccines Market
This report categorizes the preventive vaccines market across multiple dimensions:

By Type: Live or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines
By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, and other diseases
By Age Group: Pediatric, Adult, Geriatric
By Distribution Channel: Hospitals, Clinics, Pharmacies, and other outlets

Subcategories further clarify vaccine types, such as Measles, Mumps, and Rubella (MMR) under Live or Attenuated Vaccines, or the Pneumococcal Conjugate Vaccine (PCV) under Conjugate Vaccines. Others include Hepatitis B and Human Papillomavirus (HPV) vaccines among Subunit Vaccines, and DNA vaccines targeting diseases like Zika Virus and Cytomegalovirus. Recombinant Vector Vaccines include Ebola and COVID-19 vaccines, among others.

Together, these segments provide a comprehensive framework for understanding the multifaceted preventive vaccines market and its ongoing evolution.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.